KRAS and neoplasm: Multivariate Cox proportional hazard analyses incorporating primary tumor anatomic site, type of perioperative chemotherapy, treatment year, or mutational data, including KRAS mutation, BRAF mutation, or MSI, did not independently contribute to prognostication in our cohort.